Navigation Links
Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008

COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- Santaris Pharma, the Danish biopharmaceutical company developing LNA based RNA medicines, announced today that Keith McCullagh, President and Chief Executive Officer, will be presenting an overview of the company and its goals for 2008 at the Biotechnology Industry Organisation's 10th Annual CEO & Investor Conference in New York, today, Monday February 11th at 12:30 pm, US Eastern Standard Time (18:30 Central European Time). The conference is being held at the Waldorf Astoria Hotel, New York City from February 11th-13th, 2008.

A live webcast of the Santaris Pharma presentation may be accessed from the news section of the company's website,, where it will also be archived and available after the presentation.

About Santaris Pharma

Santaris Pharma is a Danish based clinical-stage biopharmaceutical company. The company was formed in 2003 and currently employs around 100 people. Santaris Pharma has the exclusive rights to LNA technology, a 3rd generation antisense chemistry used to develop new classes of RNA medicines, called RNA Antagonists and microRNA antagonists. Santaris Pharma's RNA Antagonists are targeted against tissue specific mRNAs associated with cancer, metabolic disorders and viral disease. In May 2006 Santaris Pharma completed a Euro 40m second round of equity financing and in December 2007 the Company completed a Euro 20m third round of equity financing. Santaris Pharma has a global partnership with Enzon Pharmaceuticals of New Jersey to co-develop and commercialise a series of Santaris Pharma RNA Antagonists for improving the treatment of cancer. GlaxoSmithKline has options to up to four Santaris Pharma drug candidates targeted against viral disease.

For further information please contact

Randi Krogsgaard, Director Corporate Communications

Direct phone: +45 45179879

Cell: +45 20488384


SOURCE Santaris Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... are paramount. Insertion points for in-line sensors can represent a weak spot where ... InTrac 781/784 series of retractable sensor housings , which are designed to tolerate ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
(Date:11/24/2015)... ANGELES , Nov. 24, 2015 ... biotechnology company focused on the discovery, development and commercialization ... , Ph.D., Chief Executive Officer, is scheduled to present ... 1, 2015 at 10:50 a.m. EST, at The Lotte ... City . . ...
Breaking Biology Technology:
(Date:10/29/2015)... October 29, 2015 NXTD ... company focused on the growing mobile commerce market ... that StackCommerce, a leading marketplace to discover and ... Wocket® smart wallet on StackSocial for this holiday ... or the "Company"), a biometric authentication company focused ...
(Date:10/27/2015)... 2015 In the present market scenario, security ... various industry verticals such as banking, healthcare, defense, electronic ... demand for secure & simplified access control and growing ... hacking of bank accounts, misuse of users, , and ... PC,s, laptops, and smartphones are expected to provide potential ...
(Date:10/27/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... has adopted the Synaptics ® ClearPad ® ... its newest flagship smartphones, the Nexus 5X by LG ... --> --> Synaptics works closely ... collaboration in the joint development of next generation technologies. ...
Breaking Biology News(10 mins):